Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arno Therapeutics, a clinical-stage biopharmaceutical company, has reported that the FDA has accepted the company's investigational new drug application for the use of AR-42.
Subscribe to our email newsletter
AR-42 is an orally available, novel, potent, small molecule that modifies the acetylation of histones and other molecules, and is a targeted inhibitor of the Pan-DAC and Akt pathways. Arno in-licensed the exclusive worldwide rights to AR-42 from The Ohio State University.
In preclinical studies, AR-42 has demonstrated greater potency and a competitive profile in tumors when compared with vorinostat (also known as SAHA and marketed as Zolina by Merck), the leading marketed histone deacetylase inhibitor, said Arno.